Cargando…

Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach

BACKGROUND: High grade serous ovarian cancer is one of the poorly characterized malignancies. This study aimed to elucidate the mutational events in Malaysian patients with high grade serous ovarian cancer by performing targeted sequencing on 50 cancer hotspot genes. RESULTS: Nine high grade serous...

Descripción completa

Detalles Bibliográficos
Autores principales: Ab Mutalib, Nurul-Syakima, Syafruddin, Saiful Effendi, Md Zain, Reena Rahayu, Mohd Dali, Ahmad Zailani Hatta, Mohd Yunos, Ryia Illani, Saidin, Sazuita, Jamal, Rahman, Mokhtar, Norfilza M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4242548/
https://www.ncbi.nlm.nih.gov/pubmed/25404506
http://dx.doi.org/10.1186/1756-0500-7-805
_version_ 1782345962811817984
author Ab Mutalib, Nurul-Syakima
Syafruddin, Saiful Effendi
Md Zain, Reena Rahayu
Mohd Dali, Ahmad Zailani Hatta
Mohd Yunos, Ryia Illani
Saidin, Sazuita
Jamal, Rahman
Mokhtar, Norfilza M
author_facet Ab Mutalib, Nurul-Syakima
Syafruddin, Saiful Effendi
Md Zain, Reena Rahayu
Mohd Dali, Ahmad Zailani Hatta
Mohd Yunos, Ryia Illani
Saidin, Sazuita
Jamal, Rahman
Mokhtar, Norfilza M
author_sort Ab Mutalib, Nurul-Syakima
collection PubMed
description BACKGROUND: High grade serous ovarian cancer is one of the poorly characterized malignancies. This study aimed to elucidate the mutational events in Malaysian patients with high grade serous ovarian cancer by performing targeted sequencing on 50 cancer hotspot genes. RESULTS: Nine high grade serous ovarian carcinoma samples and ten normal ovarian tissues were obtained from Universiti Kebangsaan Malaysia Medical Center (UKMMC) and the Kajang Hospital. The Ion AmpliSeq™ Cancer Hotspot Panel v2 targeting “mutation-hotspot region” in 50 most common cancer-associated genes was utilized. A total of 20 variants were identified in 12 genes. Eleven (55%) were silent alterations and nine (45%) were missense mutations. Six of the nine missense mutations were predicted to be deleterious while the other three have low or neutral protein impact. Eight genes were altered in both the tumor and normal groups (APC, EGFR, FGFR3, KDR, MET, PDGFRA, RET and SMO) while four genes (TP53, PIK3CA, STK11 and KIT) were exclusively altered in the tumor group. TP53 alterations were present in all the tumors but not in the normal group. Six deleterious mutations in TP53 (p.R175H, p.H193R, p.Y220C, p.Y163C, p.R282G and p.Y234H) were identified in eight serous ovarian carcinoma samples and none in the normal group. CONCLUSION: TP53 remains as the most frequently altered gene in high grade serous ovarian cancer and Ion Torrent Personal Genome Machine (PGM) in combination with Ion Ampliseq™ Cancer Hotspot Panel v2 were proven to be instrumental in identifying a wide range of genetic alterations simultaneously from a minute amount of DNA. However, larger series of validation targeting more genes are necessary in order to shed a light on the molecular events underlying pathogenesis of this cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1756-0500-7-805) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4242548
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42425482014-11-25 Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach Ab Mutalib, Nurul-Syakima Syafruddin, Saiful Effendi Md Zain, Reena Rahayu Mohd Dali, Ahmad Zailani Hatta Mohd Yunos, Ryia Illani Saidin, Sazuita Jamal, Rahman Mokhtar, Norfilza M BMC Res Notes Research Article BACKGROUND: High grade serous ovarian cancer is one of the poorly characterized malignancies. This study aimed to elucidate the mutational events in Malaysian patients with high grade serous ovarian cancer by performing targeted sequencing on 50 cancer hotspot genes. RESULTS: Nine high grade serous ovarian carcinoma samples and ten normal ovarian tissues were obtained from Universiti Kebangsaan Malaysia Medical Center (UKMMC) and the Kajang Hospital. The Ion AmpliSeq™ Cancer Hotspot Panel v2 targeting “mutation-hotspot region” in 50 most common cancer-associated genes was utilized. A total of 20 variants were identified in 12 genes. Eleven (55%) were silent alterations and nine (45%) were missense mutations. Six of the nine missense mutations were predicted to be deleterious while the other three have low or neutral protein impact. Eight genes were altered in both the tumor and normal groups (APC, EGFR, FGFR3, KDR, MET, PDGFRA, RET and SMO) while four genes (TP53, PIK3CA, STK11 and KIT) were exclusively altered in the tumor group. TP53 alterations were present in all the tumors but not in the normal group. Six deleterious mutations in TP53 (p.R175H, p.H193R, p.Y220C, p.Y163C, p.R282G and p.Y234H) were identified in eight serous ovarian carcinoma samples and none in the normal group. CONCLUSION: TP53 remains as the most frequently altered gene in high grade serous ovarian cancer and Ion Torrent Personal Genome Machine (PGM) in combination with Ion Ampliseq™ Cancer Hotspot Panel v2 were proven to be instrumental in identifying a wide range of genetic alterations simultaneously from a minute amount of DNA. However, larger series of validation targeting more genes are necessary in order to shed a light on the molecular events underlying pathogenesis of this cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1756-0500-7-805) contains supplementary material, which is available to authorized users. BioMed Central 2014-11-17 /pmc/articles/PMC4242548/ /pubmed/25404506 http://dx.doi.org/10.1186/1756-0500-7-805 Text en © Ab Mutalib et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ab Mutalib, Nurul-Syakima
Syafruddin, Saiful Effendi
Md Zain, Reena Rahayu
Mohd Dali, Ahmad Zailani Hatta
Mohd Yunos, Ryia Illani
Saidin, Sazuita
Jamal, Rahman
Mokhtar, Norfilza M
Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach
title Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach
title_full Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach
title_fullStr Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach
title_full_unstemmed Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach
title_short Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach
title_sort molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4242548/
https://www.ncbi.nlm.nih.gov/pubmed/25404506
http://dx.doi.org/10.1186/1756-0500-7-805
work_keys_str_mv AT abmutalibnurulsyakima molecularcharacterizationofserousovariancarcinomausingamultigenenextgenerationsequencingcancerpanelapproach
AT syafruddinsaifuleffendi molecularcharacterizationofserousovariancarcinomausingamultigenenextgenerationsequencingcancerpanelapproach
AT mdzainreenarahayu molecularcharacterizationofserousovariancarcinomausingamultigenenextgenerationsequencingcancerpanelapproach
AT mohddaliahmadzailanihatta molecularcharacterizationofserousovariancarcinomausingamultigenenextgenerationsequencingcancerpanelapproach
AT mohdyunosryiaillani molecularcharacterizationofserousovariancarcinomausingamultigenenextgenerationsequencingcancerpanelapproach
AT saidinsazuita molecularcharacterizationofserousovariancarcinomausingamultigenenextgenerationsequencingcancerpanelapproach
AT jamalrahman molecularcharacterizationofserousovariancarcinomausingamultigenenextgenerationsequencingcancerpanelapproach
AT mokhtarnorfilzam molecularcharacterizationofserousovariancarcinomausingamultigenenextgenerationsequencingcancerpanelapproach